Please assess the completion status of the following clinical trial:

Trial Title: Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-1 9 patients with mild symptoms and the results were confirmed by Antigen Test Kit or PCR for SARS-CoV-2.~* People who have symptoms consistent with COVID-19 and test positive for SARS-CoV-2 infection within 48 hours of being known.~* Participants are 18 years of age or older.~Exclusion Criteria:~* Almost recovered (generally much improved and symptoms now mild or almost absent)~* Judgement of the recruiting clinician deems ineligible.~* Previous randomisation to an arm of the trial~* Pregnancy~* Breastfeeding~* Known severe hepatic impairment.~* Known severe renal impairment.~* Currently taking Fluvoxamine, Bromhexine, Cyproheptadine, or Niclosamide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluvoxamine Arm (Type: EXPERIMENTAL): The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime.
- Fluvoxamine in Combination with Bromhexine Arm (Type: EXPERIMENTAL): The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.
- Fluvoxamine in Combination with Cyproheptadine Arm (Type: EXPERIMENTAL): The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with cyproheptadine 4 mg, 1 tablet, three times, orally after meals and should be taken every 8 hours apart, for 14 days.
- Niclosamide Arm (Type: EXPERIMENTAL): The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days.
- Niclosamide in Combination with Bromhexine Arm (Type: EXPERIMENTAL): The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days. Co-administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.
- Usual Care Arm (Type: NO_INTERVENTION): The control group received treatment according to the latest usual care medical guidelines provide by ministry of Thailand at that time.

Based on this trial design, predict the completion outcome and termination type (if applicable).